BAXTER'S NOVACOR LVAS AS ALTERNATIVE TO HEART TRANSPLANTATION
This article was originally published in The Gray Sheet
Executive Summary
BAXTER'S NOVACOR LVAS AS ALTERNATIVE TO HEART TRANSPLANTATION underwent its first placement, in an English patient on Aug. 24. The implantation marks the first time that the left ventricular assist system will be evaluated as "a long-term treatment for end-stage heart failure," Baxter says. The study, in cooperation with Papworth Hospital NHS Trust of Cambridge University, is designed as a pilot program of four participants. Twenty-five patients ultimately will be enrolled. The LVAS was developed by Baxter's Novacor division.